Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 132

1.

Fine-Tuning TLR-7-Based Therapy for Functional HBV Cure.

Bertoletti A, Le Bert N.

Hepatol Commun. 2019 Oct 1;3(10):1289-1292. doi: 10.1002/hep4.1420. eCollection 2019 Oct.

2.

Dynamics and genomic landscape of CD8+ T cells undergoing hepatic priming.

Bénéchet AP, De Simone G, Di Lucia P, Cilenti F, Barbiera G, Le Bert N, Fumagalli V, Lusito E, Moalli F, Bianchessi V, Andreata F, Zordan P, Bono E, Giustini L, Bonilla WV, Bleriot C, Kunasegaran K, Gonzalez-Aseguinolaza G, Pinschewer DD, Kennedy PTF, Naldini L, Kuka M, Ginhoux F, Cantore A, Bertoletti A, Ostuni R, Guidotti LG, Iannacone M.

Nature. 2019 Oct;574(7777):200-205. doi: 10.1038/s41586-019-1620-6. Epub 2019 Oct 2.

PMID:
31582858
3.

Therapeutic strategies for hepatitis B virus infection: towards a cure.

Fanning GC, Zoulim F, Hou J, Bertoletti A.

Nat Rev Drug Discov. 2019 Nov;18(11):827-844. doi: 10.1038/s41573-019-0037-0. Epub 2019 Aug 27. Review.

PMID:
31455905
4.

Comparative characterization of B cells specific for HBV nucleocapsid and envelope proteins in patients with chronic hepatitis B.

Le Bert N, Salimzadeh L, Gill US, Dutertre CA, Facchetti F, Tan A, Hung M, Novikov N, Lampertico P, Fletcher SP, Kennedy PTF, Bertoletti A.

J Hepatol. 2019 Jul 23. pii: S0168-8278(19)30424-6. doi: 10.1016/j.jhep.2019.07.015. [Epub ahead of print]

PMID:
31348999
5.

Excellent safety and effectiveness of high-dose myrcludex-B monotherapy administered for 48 weeks in HDV-related compensated cirrhosis: A case report of 3 patients.

Loglio A, Ferenci P, Uceda Renteria SC, Tham CYL, van Bömmel F, Borghi M, Holzmann H, Perbellini R, Trombetta E, Giovanelli S, Greco L, Porretti L, Prati D, Ceriotti F, Lunghi G, Bertoletti A, Lampertico P.

J Hepatol. 2019 Oct;71(4):834-839. doi: 10.1016/j.jhep.2019.07.003. Epub 2019 Jul 11.

PMID:
31302176
6.

Update of the statements on biology and clinical impact of occult hepatitis B virus infection.

Raimondo G, Locarnini S, Pollicino T, Levrero M, Zoulim F, Lok AS; Taormina Workshop on Occult HBV Infection Faculty Members.

J Hepatol. 2019 Aug;71(2):397-408. doi: 10.1016/j.jhep.2019.03.034. Epub 2019 Apr 18. Review.

7.

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation.

Zhao X, Hamidinia M, Choo JAL, Too CT, Ho ZZ, Ren EC, Bertoletti A, MacAry PA, Gould KG, Brzostek J, Gascoigne NRJ.

J Vis Exp. 2019 Feb 28;(144). doi: 10.3791/59126.

8.

Multifactorial heterogeneity of virus-specific T cells and association with the progression of human chronic hepatitis B infection.

Cheng Y, Zhu YO, Becht E, Aw P, Chen J, Poidinger M, de Sessions PF, Hibberd ML, Bertoletti A, Lim SG, Newell EW.

Sci Immunol. 2019 Feb 8;4(32). pii: eaau6905. doi: 10.1126/sciimmunol.aau6905.

PMID:
30737354
9.

Use of Expression Profiles of HBV-DNA Integrated Into Genomes of Hepatocellular Carcinoma Cells to Select T Cells for Immunotherapy.

Tan AT, Yang N, Lee Krishnamoorthy T, Oei V, Chua A, Zhao X, Tan HS, Chia A, Le Bert N, Low D, Tan HK, Kumar R, Irani FG, Ho ZZ, Zhang Q, Guccione E, Wai LE, Koh S, Hwang W, Chow WC, Bertoletti A.

Gastroenterology. 2019 May;156(6):1862-1876.e9. doi: 10.1053/j.gastro.2019.01.251. Epub 2019 Jan 31.

10.

HBV antiviral immunity: not all CD8 T cells are born equal.

Bertoletti A, Kennedy PTF.

Gut. 2019 May;68(5):770-773. doi: 10.1136/gutjnl-2018-317959. Epub 2019 Jan 30. No abstract available.

PMID:
30700541
11.

Spatiotemporal Differences in Presentation of CD8 T Cell Epitopes during Hepatitis B Virus Infection.

Khakpoor A, Ni Y, Chen A, Ho ZZ, Oei V, Yang N, Giri R, Chow JX, Tan AT, Kennedy PT, Maini M, Urban S, Bertoletti A.

J Virol. 2019 Feb 5;93(4). pii: e01457-18. doi: 10.1128/JVI.01457-18. Print 2019 Feb 15.

12.

Cross-Reactivity and Anti-viral Function of Dengue Capsid and NS3-Specific Memory T Cells Toward Zika Virus.

Lim MQ, Kumaran EAP, Tan HC, Lye DC, Leo YS, Ooi EE, MacAry PA, Bertoletti A, Rivino L.

Front Immunol. 2018 Oct 1;9:2225. doi: 10.3389/fimmu.2018.02225. eCollection 2018.

13.

Molecular Recalibration of PD-1+ Antigen-Specific T Cells from Blood and Liver.

Otano I, Escors D, Schurich A, Singh H, Robertson F, Davidson BR, Fusai G, Vargas FA, Tan ZMD, Aw JYJ, Hansi N, Kennedy PTF, Xue SA, Stauss HJ, Bertoletti A, Pavesi A, Maini MK.

Mol Ther. 2018 Nov 7;26(11):2553-2566. doi: 10.1016/j.ymthe.2018.08.013. Epub 2018 Aug 16.

14.

PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection.

Salimzadeh L, Le Bert N, Dutertre CA, Gill US, Newell EW, Frey C, Hung M, Novikov N, Fletcher S, Kennedy PT, Bertoletti A.

J Clin Invest. 2018 Oct 1;128(10):4573-4587. doi: 10.1172/JCI121957. Epub 2018 Aug 7.

15.

Corrigendum: Characterizing the Role of Monocytes in T Cell Cancer Immunotherapy Using a 3D Microfluidic Model.

Lee SWL, Adriani G, Ceccarello E, Pavesi A, Tan AT, Bertoletti A, Kamm RD, Wong SC.

Front Immunol. 2018 Jul 24;9:1719. doi: 10.3389/fimmu.2018.01719. eCollection 2018.

16.

Nonstimulatory peptide-MHC enhances human T-cell antigen-specific responses by amplifying proximal TCR signaling.

Zhao X, Sankaran S, Yap J, Too CT, Ho ZZ, Dolton G, Legut M, Ren EC, Sewell AK, Bertoletti A, MacAry PA, Brzostek J, Gascoigne NRJ.

Nat Commun. 2018 Jul 13;9(1):2716. doi: 10.1038/s41467-018-05288-0.

17.

Editorial overview: Antiviral strategies: Virological and immunological basis for HBV cure.

Urban S, Bertoletti A.

Curr Opin Virol. 2018 Jun;30:iv-vi. doi: 10.1016/j.coviro.2018.05.001. No abstract available.

PMID:
29866361
18.

Characterizing the Role of Monocytes in T Cell Cancer Immunotherapy Using a 3D Microfluidic Model.

Lee SWL, Adriani G, Ceccarello E, Pavesi A, Tan AT, Bertoletti A, Kamm RD, Wong SC.

Front Immunol. 2018 Mar 6;9:416. doi: 10.3389/fimmu.2018.00416. eCollection 2018. Erratum in: Front Immunol. 2018 Jul 24;9:1719.

19.

Nonlytic Lymphocytes Engineered to Express Virus-Specific T-Cell Receptors Limit HBV Infection by Activating APOBEC3.

Koh S, Kah J, Tham CYL, Yang N, Ceccarello E, Chia A, Chen M, Khakpoor A, Pavesi A, Tan AT, Dandri M, Bertoletti A.

Gastroenterology. 2018 Jul;155(1):180-193.e6. doi: 10.1053/j.gastro.2018.03.027. Epub 2018 Mar 14.

PMID:
29550589
20.

CD137L dendritic cells induce potent response against cancer-associated viruses and polarize human CD8+ T cells to Tc1 phenotype.

Dharmadhikari B, Nickles E, Harfuddin Z, Ishak NDB, Zeng Q, Bertoletti A, Schwarz H.

Cancer Immunol Immunother. 2018 Jun;67(6):893-905. doi: 10.1007/s00262-018-2144-x. Epub 2018 Mar 5.

PMID:
29508025

Supplemental Content

Loading ...
Support Center